Currently, there are 236.62M common shares owned by the public and among those 230.23M shares have been available to trade.
The company’s stock has a 5-day price change of 24.80% and 51.39% over the past three months. ADMA shares are trading 42.92% year to date (YTD), with the 12-month market performance up to 279.41% higher. It has a 12-month low price of $6.40 and touched a high of $23.64 over the same period. ADMA has an average intraday trading volume of 3.07 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 20.22%, 30.67%, and 38.33% respectively.
Institutional ownership of Adma Biologics Inc (NASDAQ: ADMA) shares accounts for 86.06% of the company’s 236.62M shares outstanding.
It has a market capitalization of $5.85B and a beta (3y monthly) value of 0.58. The stock’s trailing 12-month PE ratio is 30.28, while the earnings-per-share (ttm) stands at $0.81. The company has a PEG of 1.01 and a Quick Ratio of 2.90 with the debt-to-equity ratio at 0.24. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.79% over the week and 7.75% over the month.
Analysts forecast that Adma Biologics Inc (ADMA) will achieve an EPS of 0.13 for the current quarter, 0.16 for the next quarter and 0.87 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.13 while analysts give the company a high EPS estimate of 0.13. Comparatively, EPS for the current quarter was 0.08 a year ago. Earnings per share for the fiscal year are expected to increase by 40.83%, and 40.78% over the next financial year.
Looking at the support for the ADMA, a number of firms have released research notes about the stock. Raymond James stated their Strong Buy rating for the stock in a research note on July 19, 2023, with the firm’s price target at $5. Mizuho coverage for the Adma Biologics Inc (ADMA) stock in a research note released on October 13, 2022 offered a Buy rating with a price target of $5. Raymond James was of a view on November 11, 2021 that the stock is Strong Buy, while Cantor Fitzgerald gave the stock Overweight rating on November 09, 2021, issuing a price target of $4.50. Jefferies on their part issued Buy rating on June 04, 2019.
